Table 2.
Clinicopathologic Characteristics of Clinically Diagnosed AUA Low-Risk Disease.
| Characteristic | African American % (n = 57) | Caucasian % (n = 344) | p value |
|---|---|---|---|
| Age (median years) | 55 | 59 | p < .001 |
| PSA at biopsy (median ng/mL) | 4.7 | 4.8 | p < .17 |
| Clinical stage | p < .48 | ||
| T1c | 13.6% (n = 43) | 86.4% (n = 274) | |
| T2a | 16.7% (n = 14) | 83.3% (n = 70) | |
| Pathologic upgrading | 29.8% (n = 17) | 44.5% (n = 153) | p < .04 |
| Pathological stage* | p < .92 | ||
| T2x | 14.3% (n = 48) | 85.7% (n = 287) | |
| T3x | 14.1% (n = 9) | 85.9% (n = 55) | |
| Extracapsular extension | 7.0% (n = 4) | 14.8% (n = 51) | p < .16 |
| Margins | 38.6% (n = 22) | 44.7% (n = 116) | p < .76 |
| Seminal vesicles | 5.3% (n = 3) | 1.7% (n = 6) | p < .10 |
| Adverse pathology | 15.8% (n = 9) | 17.7% (n = 61) | p < .72 |
| Prostate weight (median, g) | 32 | 35 | p < .04 |
| % Tumor (median) | 5 | 5 | p < .86 |
Note. AUA = American Urological Association; PSA = prostate-specific antigen.
*
One Caucasian listed as pT4.